Activated lymphocytes in the marrow cell suspension decrease the mafosfamide-induced CFU-GM cytotoxicity

Area of Science:

• Hematology
• Oncology
• Cell Biology

Background:

• Ex vivo bone marrow purging is essential for autologous transplantation to eliminate residual tumor cells.
• Mafosfamide (maf) is a chemotherapeutic agent used in bone marrow purging.
• The influence of non-erythroid cells on mafosfamide's efficacy requires further investigation.

Purpose of the Study:

• To determine if various bone marrow cells, beyond erythrocytes, affect mafosfamide's cytotoxic activity.
• To assess the impact of granulocytes, leukemia cells, and lymphocytes on mafosfamide-mediated purging.

Main Methods:

• Incubation of bone marrow cell suspensions with mafosfamide.
• Co-incubation with normal granulocytes, acute myeloid leukemia (AML) blast cells, and chronic lymphocytic leukemia (CLL) lymphoma cells.
• Assessment of mafosfamide's effect on CFU-GM growth inhibition.
• Experiments with resting and activated (phytohaemagglutinin- and pokeweed mitogen-stimulated) lymphocytes.

Main Results:

• Mafosfamide's cytotoxic effect on CFU-GM was not altered by the presence of normal granulocytes, AML blast cells, or CLL lymphoma cells.
• Resting lymphocytes did not influence mafosfamide's efficacy.
• Activated lymphocytes significantly reduced mafosfamide-induced cytotoxicity against CFU-GM.

Conclusions:

• Activated lymphocytes, in addition to erythrocytes, can modulate the effectiveness of mafosfamide during ex vivo bone marrow purging.
• These findings highlight the importance of considering the cellular composition of bone marrow during purging protocols.
• Further research may lead to refined purging strategies for improved cancer treatment outcomes.